ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced a U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has provided feedback to support the adoption of leadless pacing technology in the U.S. The feedback follows a panel discussion today on leadless pacing technology that included a broad overview of the clinical experience with the St. Jude Medical Nanostim™ leadless pacemaker.
